Trials / Active Not Recruiting
Active Not RecruitingNCT03935971
The Effects of Dupilumab on Allergic Contact Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Detailed description
The investigators will recruit 30 patients with allergic contact dermatitis who have not improved with allergen avoidance up to 18 months after patch testing, but where allergic contact dermatitis is still suspected. Subjects will receive 10 weeks of dupilumab, and both clinical data and tissue samples will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | See arm/group description |
Timeline
- Start date
- 2019-12-18
- Primary completion
- 2024-12-31
- Completion
- 2026-07-31
- First posted
- 2019-05-02
- Last updated
- 2026-02-27
- Results posted
- 2026-02-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03935971. Inclusion in this directory is not an endorsement.